Notably, tumors of patients with metastatic breast cancer have higher MYOF levels (52.5%) than adjacent non-cancerous tissues (12.5%) and tumors from patients with in situ breast carcinoma (25%) (Supplementary Fig. 12b). This evidence concerns the gene MYOF and lobular breast carcinoma in situ.